The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts
- 24 November 2009
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 37 (1) , 180-186
Abstract
Alendronate is a well-established treatment for osteoporosis and suppresses bone resorption by a direct effect on osteoclasts and their precursors. The effect of alendronate on osteoclasts is produced, at least in part, by the receptor activator of nuclear factor kappaB ligand (RANKL) and the osteoprotegerin (OPG) synthesized by the osteoblasts. This study analyzes the effect of alendronate in cell viability, phosphatase alkaline (ALP) activity and RANKL, and OPG expression in primary human osteoblasts (hOB). Alendronate at concentrations lower than 10−5 M did not have a toxic effect on hOB in vitro and did not modify the ALP activity at least for 72 h. Alendronate did not change OPG expression in basal, 10% FBS, and vitamin D-treated cultures. Similar results were observed at the protein level. Unexpectedly, alendronate at 10−7 and 10−5 M concentrations increased the RANKL expression with the presence of vitamin D in differentiated hOB and this induction of RANKL mRNA levels by alendronate was dose-dependent. However, this effect was not observed in basal and 10% FBS culture conditions. Thus, we conclude that alendronate does not affect the ALP activity and OPG gene expression in differentiated hOB, but may increase RANKL gene expression induced by vitamin D.Keywords
This publication has 39 references indexed in Scilit:
- Stimulation of osteogenic differentiation and inhibition of adipogenic differentiation in bone marrow stromal cells by alendronate via ERK and JNK activationBone, 2008
- Functions of RANKL/RANK/OPG in bone modeling and remodelingArchives of Biochemistry and Biophysics, 2008
- Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and DiseaseEndocrine Reviews, 2007
- Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogsBone, 2006
- Osteoblast proliferation and maturation by bisphosphonatesBiomaterials, 2004
- Alendronate Interacts With the Inhibitory Effect of 1,25(OH)2D3 on Parathyroid Hormone-Related Protein Expression In Human Osteoblastic CellsJournal of Bone and Mineral Research, 2003
- Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expressionExperimental & Molecular Medicine, 2002
- Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human OsteoblastsBiochemical and Biophysical Research Communications, 2002
- Extracellular Signal-Regulated Kinases and Calcium Channels Are Involved in the Proliferative Effect of Bisphosphonates on Osteoblastic Cells In VitroJournal of Bone and Mineral Research, 2001
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999